Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 4
2022 7
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Defining the risk of SARS-CoV-2 variants on immune protection.
DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, Bloom JD, Bloyet LM, Bonenfant G, Boon ACM, Boritz EA, Bratt DL, Bricker TL, Brown L, Buchser WJ, Carreño JM, Cohen-Lavi L, Darling TL, Davis-Gardner ME, Dearlove BL, Di H, Dittmann M, Doria-Rose NA, Douek DC, Drosten C, Edara VV, Ellebedy A, Fabrizio TP, Ferrari G, Fischer WM, Florence WC, Fouchier RAM, Franks J, García-Sastre A, Godzik A, Gonzalez-Reiche AS, Gordon A, Haagmans BL, Halfmann PJ, Ho DD, Holbrook MR, Huang Y, James SL, Jaroszewski L, Jeevan T, Johnson RM, Jones TC, Joshi A, Kawaoka Y, Kercher L, Koopmans MPG, Korber B, Koren E, Koup RA, LeGresley EB, Lemieux JE, Liebeskind MJ, Liu Z, Livingston B, Logue JP, Luo Y, McDermott AB, McElrath MJ, Meliopoulos VA, Menachery VD, Montefiori DC, Mühlemann B, Munster VJ, Munt JE, Nair MS, Netzl A, Niewiadomska AM, O'Dell S, Pekosz A, Perlman S, Pontelli MC, Rockx B, Rolland M, Rothlauf PW, Sacharen S, Scheuermann RH, Schmidt SD, Schotsaert M, Schultz-Cherry S, Seder RA, Sedova M, Sette A, Shabman RS, Shen X, Shi PY, Shukla M, Simon V, Stumpf S, Sullivan NJ, Thackray LB, Theiler J, Thomas PG, Trifkovic S, Türeli S, Turn… See abstract for full author list ➔ DeGrace MM, et al. Nature. 2022 May;605(7911):640-652. doi: 10.1038/s41586-022-04690-5. Epub 2022 Mar 31. Nature. 2022. PMID: 35361968 Free PMC article. Review.
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M, De Giglio MAR, Roviello GN. Costanzo M, et al. Curr Med Chem. 2022;29(1):4-18. doi: 10.2174/0929867328666210521164809. Curr Med Chem. 2022. PMID: 34355678 Review.
This work will give an overview of what is reported in the recent literature on vaccines (under investigation or already developed like BNT162b2, mRNA-1273, and ChAdOx1-S) effective against the most pathogenic Coronaviruses (SARS-CoV-1, MERS-CoV-1, and SARS-CoV-2), with of …
This work will give an overview of what is reported in the recent literature on vaccines (under investigation or already developed like BNT1 …
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, Nagata BM, Bock KW, Phung E, Schäfer A, Dinnon KH 3rd, Chang LA, Loomis RJ, Boyoglu-Barnum S, Alvarado GS, Sullivan NJ, Edwards DK, Morabito KM, Mascola JR, Carfi A, Corbett KS, Moore IN, Baric RS, Graham BS, Ruckwardt TJ. DiPiazza AT, et al. Immunity. 2021 Aug 10;54(8):1869-1882.e6. doi: 10.1016/j.immuni.2021.06.018. Epub 2021 Jul 2. Immunity. 2021. PMID: 34270939 Free PMC article.
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of severe acute respiratory syndrome (SARS) and MERS coronavirus vaccines. We used the SARS coronavirus 2 (SARS-CoV-2) mouse-adapted, passage 10, lethal challenge vir …
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of severe acute respiratory syndr …
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Fang Z, et al. bioRxiv. 2022 Feb 28:2022.02.14.480449. doi: 10.1101/2022.02.14.480449. Preprint. bioRxiv. 2022. PMID: 35194606 Free PMC article. Updated.
Mice that received two-dose WT LNP-mRNA, the one mimicking the commonly used Pfizer/Moderna mRNA vaccine, showed a >40-fold reduction in neutralization potency against Omicron variant than that against WT two weeks post second dose, which further reduced to background l …
Mice that received two-dose WT LNP-mRNA, the one mimicking the commonly used Pfizer/Moderna mRNA vaccine, showed a >40-fold reduct …
Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.
Noor R. Noor R. Curr Clin Microbiol Rep. 2021;8(3):178-185. doi: 10.1007/s40588-021-00162-y. Epub 2021 Mar 3. Curr Clin Microbiol Rep. 2021. PMID: 33686365 Free PMC article. Review.
RECENT FINDINGS: A range of investigations on the SARS-CoV-2 genomics, on its similarities with SARS-CoV-1, and with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been accomplished and the host immune dodging mechanisms by the SARS-CoV-2 have been unrave …
RECENT FINDINGS: A range of investigations on the SARS-CoV-2 genomics, on its similarities with SARS-CoV-1, and with the Middle East respira …
A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
Abdolmaleki G, Taheri MA, Paridehpour S, Mohammadi NM, Tabatabaei YA, Mousavi T, Amin M. Abdolmaleki G, et al. Daru. 2022 Dec;30(2):379-406. doi: 10.1007/s40199-022-00446-8. Epub 2022 Sep 2. Daru. 2022. PMID: 36050585 Free PMC article. Review.
Due to the COVID-19 pandemic, many companies have initiated investigations on developing an efficient and safe vaccine against the virus. From Moderna and Pfizer in the United States to PastocoVac in Pasteur Institute of Iran and the University of Oxford in the United King …
Due to the COVID-19 pandemic, many companies have initiated investigations on developing an efficient and safe vaccine against the virus. Fr …
A Proposal to Refer to Four Coronaviruses of Limited Human Virulence "Common Cold Coronaviruses".
McIntosh K, Perlman S, Monto A, Englund JA. McIntosh K, et al. J Infect Dis. 2022 Dec 13;226(12):2047-2049. doi: 10.1093/infdis/jiac355. J Infect Dis. 2022. PMID: 36052654 Free PMC article.
This will differentiate these previously described coronaviruses from those causing more severe disease in humans - including the viruses severe acute respiraotry syndrome coronavirus (SARS-CoV), the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2... …
This will differentiate these previously described coronaviruses from those causing more severe disease in humans - including the viruses se …
SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review.
Muhammed Y, Yusuf Nadabo A, Pius M, Sani B, Usman J, Anka Garba N, Mohammed Sani J, Opeyemi Olayanju B, Zeal Bala S, Garba Abdullahi M, Sambo M. Muhammed Y, et al. Biosaf Health. 2021 Oct;3(5):249-263. doi: 10.1016/j.bsheal.2021.07.003. Epub 2021 Jul 21. Biosaf Health. 2021. PMID: 34396086 Free PMC article. Review.
The virus (SARS-CoV-2) is more infectious than the previously detected coronaviruses (MERS and SARS). Findings from many studies have revealed that S protein and RdRp are good targets for drug repositioning, novel therapeutic development (antibodies and small molecule drug …
The virus (SARS-CoV-2) is more infectious than the previously detected coronaviruses (MERS and SARS). Findings from many studies have …
CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses.
Woldemeskel BA, Dykema AG, Garliss CC, Cherfils S, Smith KN, Blankson JN. Woldemeskel BA, et al. J Clin Invest. 2022 Mar 1;132(5):e156083. doi: 10.1172/JCI156083. J Clin Invest. 2022. PMID: 35061630 Free PMC article. Clinical Trial.
In this study, we identified a SARS-CoV-2 spike protein epitope (S815-827) that is conserved in coronaviruses from different genera and subgenera, including SARS-CoV, MERS-CoV, multiple bat coronaviruses, and a feline coronavirus. Our results showed that S815-827 was recog …
In this study, we identified a SARS-CoV-2 spike protein epitope (S815-827) that is conserved in coronaviruses from different genera and subg …
13 results